Forteo

Product manufactured by Eli Lilly And Company

Application Nr Approved Date Route Status External Links
NDA021318 None Subcutaneous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Forteo Is A Parathyroid Hormone Analog, (Pth 1-34), Indicated For: Treatment Of Postmenopausal Women With Osteoporosis At High Risk For Fracture ( 1.1 ) Increase Of Bone Mass In Men With Primary Or Hypogonadal Osteoporosis At High Risk For Fracture ( 1.2 ) Treatment Of Men And Women With Osteoporosis Associated With Sustained Systemic Glucocorticoid Therapy At High Risk For Fracture ( 1.3 ) 1.1 Treatment Of Postmenopausal Women With Osteoporosis At High Risk For Fracture Forteo Is Indicated For The Treatment Of Postmenopausal Women With Osteoporosis At High Risk For Fracture, Defined As A History Of Osteoporotic Fracture, Multiple Risk Factors For Fracture, Or Patients Who Have Failed Or Are Intolerant To Other Available Osteoporosis Therapy. In Postmenopausal Women With Osteoporosis, Forteo Reduces The Risk Of Vertebral And Nonvertebral Fractures [See Clinical Studies ( 14.1 )]. 1.2 Increase Of Bone Mass In Men With Primary Or Hypogonadal Osteoporosis At High Risk For Fracture Forteo Is Indicated To Increase Bone Mass In Men With Primary Or Hypogonadal Osteoporosis At High Risk For Fracture, Defined As A History Of Osteoporotic Fracture, Multiple Risk Factors For Fracture, Or Patients Who Have Failed Or Are Intolerant To Other Available Osteoporosis Therapy [See Clinical Studies ( 14.2 )]. 1.3 Treatment Of Men And Women With Glucocorticoid-Induced Osteoporosis At High Risk For Fracture Forteo Is Indicated For The Treatment Of Men And Women With Osteoporosis Associated With Sustained Systemic Glucocorticoid Therapy (Daily Dosage Equivalent To 5 Mg Or Greater Of Prednisone) At High Risk For Fracture, Defined As A History Of Osteoporotic Fracture, Multiple Risk Factors For Fracture, Or Patients Who Have Failed Or Are Intolerant To Other Available Osteoporosis Therapy [See Clinical Studies ( 14.3 )].

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Teriparatide

Comments